Clinical Trials Browser

Neoplasms

NCT02693535 2026-04-02

TAPUR

Phase 2 Recruiting

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT06031233 2026-03-30

MINUTE

Phase 4 Recruiting

776 enrolled

Tumor-Agnostic

Neoplasms

NCT05468359 2026-03-16

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Phase 1/2 Recruiting

64 enrolled

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT05152472 2026-01-08

ATEZOGIST

Phase 2 Recruiting

110 enrolled

GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

NCT06551142 2025-12-18

PanTumor-101

Phase 1 Recruiting

590 enrolled

Tumor-Agnostic

Neoplasms

NCT05722886 2025-11-24

DETERMINE

Phase 2/3 Recruiting

825 enrolled

LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT05770102 2025-11-24

DETERMINE

Phase 2/3 Recruiting

30 enrolled

DermatologicGastrointestinalGynecologicLymphoid

Lymphoproliferative Disorders, Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Colorectal Neoplasms, Endometrial Neoplasms

NCT05394337 2025-10-09

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

Phase 1/2 Recruiting

10 enrolled

Tumor-Agnostic

Neoplasms

NCT06463665 2025-09-26

VIRO-25

Phase 2 Recruiting

142 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

300 enrolled

Tumor-Agnostic

Neoplasms

NCT03708224 2025-01-28

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Phase 2 Recruiting

55 enrolled

Head & Neck

Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms

NCT03767075 2024-04-25

BoB

Phase 2 Recruiting

1,000 enrolled

Tumor-Agnostic

Neoplasms

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

1,550 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

UmbrellaMAX

TAPUR

MINUTE

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

ATEZOGIST

PanTumor-101

DETERMINE

DETERMINE

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

VIRO-25

ProTarget

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

BoB

DRUP